Factors Associated With Survival Following Radium‐223 Treatment for Metastatic Castration‐resistant Prostate Cancer

[1]  E. Heath,et al.  Radium-223 in Heavily Pretreated Metastatic Castrate-Resistant Prostate Cancer. , 2016, Clinical genitourinary cancer.

[2]  R. Laing,et al.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial , 2016, The Lancet.

[3]  C. Parker,et al.  Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  E. Rohren,et al.  Factors affecting 223Ra therapy: clinical experience after 532 cycles from a single institution , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  David F Jarrard,et al.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.

[6]  P. Fox,et al.  Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival , 2015, The Journal of Nuclear Medicine.

[7]  Sten Nilsson,et al.  Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. , 2014, The Lancet. Oncology.

[8]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[9]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[10]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.